A step-by-step microRNA guide to cancer development and metastasis

Μαρκόπουλος, Γεώργιος; Roupakia, Eugenia; Tokamani, Maria; Chavdoula, Evangelia; Hatziapostolou, Maria; Polytarchou, Christos; Marcu, Kenneth B.; Papavassiliou, Athanasios G.; Sandaltzopoulos, Raphael; Kolettas, Evangelos

doi:10.1007/s13402-017-0341-9

Cited by 135 publications

(131 citation statements)

References 385 publications

Supporting

Mentioning

124

Contrasting

Unclassified

Order By: Relevance

“…MicroRNAs (miRNAs) are small non‐coding RNAs of ~22 nucleotides in length that play important roles in cell growth, development, differentiation, and apoptosis . Studies have shown that miRNAs are clearly differentially expressed in different cancer types, and that the expression of certain miRNAs can serve as both a marker for cancer development and a target for cancer treatment, suggesting that miRNAs may be licensed as oncogenes or tumor suppressors . MiR‐196b promotes LC cell migration and erosion by targeting to reduce GATA6 levels .…”

Section: Gata6 and Human Cancersmentioning

confidence: 99%

“…28 Studies have shown that miRNAs are clearly differentially expressed in different cancer types, and that the expression of certain miRNAs can serve as both a marker for cancer development and a target for cancer treatment, suggesting that miRNAs may be licensed as oncogenes or tumor suppressors. [29][30][31][32][33] MiR-196b promotes LC cell migration and erosion by targeting to reduce GATA6 levels. 34 However, a comprehensive study of the relationship between GATA6 and LC can be found to be controversial in the role of GATA6 in LC.…”

Section: Gata6 and Lung Cancermentioning

confidence: 99%

See 1 more Smart Citation

Multiple roles and regulatory mechanisms of the transcription factor GATA6 in human cancers

Sun

Yan

2019

Clinical Genetics

View full text Add to dashboard Cite

Cancer is a common type of non-communicable disease, and its morbidity and mortality are rapidly increasing. It is expected to become the largest obstacle to the promotion of global human health in the future. Some transcription factors that play important regulatory roles in embryogenesis and subsequent tissue maintenance can be selectively amplified during tumorigenesis. Due to its high expression in the embryonic endoderm and mesoderm, GATA6 plays a crucial role in the normal development of early human heart, lung, digestive system, adrenal glands, breasts, ovaries, retina, skin, and nervous system. Up to now, overexpression of the GATA6 gene has been shown to play an important role in several cancers, including lung cancer, digestive system tumors, breast cancer, and ovarian cancer. However, the human body is a complex organism, which causes the transcription factor GATA6 to have multiple roles in cancer. In this review, we summarize the multiple roles of transcription factor GATA6 in various cancers and its regulatory mechanisms. The aim is to better understand the relationship between GATA6 gene expression and cancer development and to provide new insights for exploring potential therapeutic targets.

show abstract

Section: Gata6 and Human Cancersmentioning

confidence: 99%

Section: Gata6 and Lung Cancermentioning

confidence: 99%

Multiple roles and regulatory mechanisms of the transcription factor GATA6 in human cancers

Sun

Yan

2019

Clinical Genetics

View full text Add to dashboard Cite

show abstract

“…There are several hallmarks that provide cancer cells with their notable characteristics [5]. It is also well known that multiple cellular signaling pathways and (extra) cellular components may govern the development of this disease [5, 6], and it has amply been shown that exogenous and endogenous carcinogens may cause mutations in the genome, driving the conversion of normal cells into cancerous cells [6, 7]. Cancer may also present itself as a genetic disease, since cancer-causing mutations in tumor suppressor genes and/or DNA repair genes may be transferred from one generation to the next [8].…”

Section: Introductionmentioning

confidence: 99%

Induction of apoptosis via proteasome inhibition in leukemia/lymphoma cells by two potent piperidones

et al. 2018

View full text Add to dashboard Cite

Purpose Previously, compounds containing a piperidone structure have been shown to be highly cytotoxic to cancer cells. Recently, we found that the piperidone compound P2 exhibits a potent anti-neoplastic activity against human breast cancer-derived cells. Here, we aimed to evaluate two piperidone compounds, P1 and P2, for their potential anti-neoplastic activity against human leukemia/lymphoma-derived cells. Methods Cytotoxicity and apoptosis induction were evaluated using MTS, annexin V-FITC/PI and mitochondrial membrane potential polychromatic assays to confirm the mode of action of the piperidone compounds. The effects of compound P1 and P2 treatment on gene expression were assessed using AmpliSeq analysis and, subsequently, confirmed by RT-qPCR and Western blotting. Results We found that the two related piperidone compounds P1 and P2 selectively killed the leukemia/lymphoma cells tested at nanomolar concentrations through induction of the intrinsic apoptotic pathway, as demonstrated by mitochondrial depolarization and caspase-3 activation. AmpliSeq-based transcriptome analyses of the effects of compounds P1 and P2 on HL-60 acute leukemia cells revealed a differential expression of hundreds of genes, 358 of which were found to be affected by both. Additional pathway analyses revealed that a significant number of the common genes were related to the unfolded protein response, implying a possible role of the two compounds in the induction of proteotoxic stress. Subsequent analyses of the transcriptome data revealed that P1 and P2 induced similar gene expression alterations as other well-known proteasome inhibitors. Finally, we found that Noxa, an important mediator of the activity of proteasome inhibitors, was significantly upregulated at both the mRNA and protein levels, indicating a possible role in the cytotoxic mechanism induced by P1 and P2. Conclusions Our data indicate that the cytotoxic activity of P1 and P2 on leukemia/lymphoma cells is mediated by proteasome inhibition, leading to activation of pro-apoptotic pathways.

show abstract

“…Aberrant miRNAs can function as either oncogenes or tumor suppressors in various types of carcinomas. 17 Overexpression of miR-196b upregulates the expression levels of VIM and MMP-2 and downregulates the expression of CDH1, thereby promoting the metastasis of non-small cell lung cancer by inducing epithelial-mesenchymal transition (EMT) signaling. 18 In addition, miR-19a, miR-24, miR-155, and miR-181b can be used to assess the degree of cancer risk in breast cancer patients.…”

mentioning

confidence: 99%

MicroRNA‐132‐3p inhibits tumor malignant progression by regulating lysosomal‐associated protein transmembrane 4 beta in breast cancer

Zhang

2019

Cancer Science

View full text Add to dashboard Cite

Lysosomal‐associated protein transmembrane 4 beta (LAPTM4B), a proto‐oncogene, has been shown to be a positive modulator in cancer progression. However, the mechanism of LAPTM4B regulation is not fully elucidated. Aberrant microRNAs (miRNAs) can regulate gene expression by interfering with target transcripts and/or translation to exert tumor‐suppressive or oncogenic effects in breast cancer. In the present study, miR‐132‐3p, which was predicted by relevant software, was confirmed to directly bind to the 3′ untranslated region (3′UTR) of LAPTM4B and negatively regulate its expression in luciferase reporter and western blot assays. Subsequently, we validated that miR‐132‐3p was downregulated in breast cancer tissues. Receiver‐operating characteristic curve analysis indicated that miR‐132‐3p had accurate diagnostic value, and a Kaplan‐Meier and Cox regression model showed that miR‐132‐3p was a potential prognostic marker for recurrence, showing low levels in breast cancer patients. In addition, we showed that miR‐132‐3p was inversely correlated with LAPTM4B expression in the above samples. Functionally, miR‐132‐3p suppressed the migration and invasion of breast carcinoma cells through LAPTM4B by mediating epithelial‐mesenchymal transition signals, and partially reversed the carcinogenic effects of LAPTM4B by inhibiting the PI3K‐AKT‐mTOR signaling pathway. Taken together, these findings provide the first comprehensive analysis of miR‐132‐3p as a direct LAPTM4B‐targeted miRNA, and shed light on miR‐132‐3p/LAPTM4B as a significant functional axis involved in the oncogenesis and metastasis of breast cancer.

show abstract

A step-by-step microRNA guide to cancer development and metastasis

Cited by 135 publications

References 385 publications

Multiple roles and regulatory mechanisms of the transcription factor GATA6 in human cancers

Multiple roles and regulatory mechanisms of the transcription factor GATA6 in human cancers

Induction of apoptosis via proteasome inhibition in leukemia/lymphoma cells by two potent piperidones

MicroRNA‐132‐3p inhibits tumor malignant progression by regulating lysosomal‐associated protein transmembrane 4 beta in breast cancer

Contact Info

Product

Resources

About